Ainos Pursues Licensing Partners To Accelerate Five Candidates Of Its Low-dose Oral Interferon Formulation VELDONA To Phase 3 Trials And Commercialization
Ainos Pursues Licensing Partners To Accelerate Five Candidates Of Its Low-dose Oral Interferon Formulation VELDONA To Phase 3 Trials And Commercialization
Ainos尋求授權合作伙伴加快其低劑量口服幹擾素配方VELDONA的五個候選產品進入第三階段試驗和商業化
Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it is pursuing out-licensing opportunities for five new drug candidates for its low-dose oral interferon-alpha ("IFNα") formulation, VELDONA. Ainos has completed Phase 2 trials for the five new drug candidates and will work with potential partners to accelerate the candidates to Phase 3 trials and eventual commercialization of VELDONA.
愛諾斯公司(納斯達克代碼：AIMD)(納斯達克代碼：AIMDW)(以下簡稱“公司”)是一家多元化的醫療科技公司，專注於開發新型護理點檢測、低劑量幹擾素療法和合成核糖核酸驅動的預防藥物。該公司今天宣佈，它正在為其低劑量口服幹擾素-α(“α”)配方VELDONA的五種新藥候選藥物尋求許可外機會。Ainos已經完成了5種候選新藥的第二階段試驗，並將與潛在合作伙伴合作，加快候選藥物進入第三階段試驗並最終實現VELDONA的商業化。
The following five indications have completed Phase 2 trials. Ainos aims to enter out...
以下五種適應症已完成第二階...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。